These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1149 related items for PubMed ID: 25428253

  • 21. Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.
    Abu Rumeileh S, Lattanzio F, Stanzani Maserati M, Rizzi R, Capellari S, Parchi P.
    J Alzheimers Dis; 2017; 55(4):1471-1480. PubMed ID: 27886009
    [Abstract] [Full Text] [Related]

  • 22. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
    Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der Flier W, Aalten P, Teunissen C, Barkhof F, Blennow K, Wolz R, Rueckert D, Verhey F, Visser PJ.
    Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
    [Abstract] [Full Text] [Related]

  • 23. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X, Shi H, Hou L, Zhong X, Chen X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chen J, Fang Y, He H, Ning Y.
    Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
    [Abstract] [Full Text] [Related]

  • 24. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK.
    J Alzheimers Dis; 2011 May; 25(4):583-94. PubMed ID: 21460434
    [Abstract] [Full Text] [Related]

  • 25. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
    Wallin AK, Blennow K, Andreasen N, Minthon L.
    Dement Geriatr Cogn Disord; 2006 May; 21(3):131-8. PubMed ID: 16391474
    [Abstract] [Full Text] [Related]

  • 26. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO.
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.
    Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
    [Abstract] [Full Text] [Related]

  • 28. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
    Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251
    [Abstract] [Full Text] [Related]

  • 29. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E, Londos E, Ballard C, Alves G, Zetterberg H, Blennow K, Skogseth R, Minthon L, Aarsland D.
    J Neurol Neurosurg Psychiatry; 2011 Feb 01; 82(2):160-4. PubMed ID: 21047883
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.
    J Alzheimers Dis; 2010 Feb 01; 21(2):471-8. PubMed ID: 20555147
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.
    Mouton-Liger F, Paquet C, Dumurgier J, Lapalus P, Gray F, Laplanche JL, Hugon J, Groupe d'Investigation du Liquide Céphalorachidien Study Network.
    Biol Psychiatry; 2012 May 01; 71(9):829-35. PubMed ID: 22281122
    [Abstract] [Full Text] [Related]

  • 38. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.
    Kettunen P, Larsson S, Holmgren S, Olsson S, Minthon L, Zetterberg H, Blennow K, Nilsson S, Sjölander A.
    J Alzheimers Dis; 2015 May 01; 44(4):1313-22. PubMed ID: 25420549
    [Abstract] [Full Text] [Related]

  • 39. Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.
    Sjögren M, Andreasen N, Blennow K.
    Clin Chim Acta; 2003 Jun 01; 332(1-2):1-10. PubMed ID: 12763273
    [Abstract] [Full Text] [Related]

  • 40. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
    Schaffer C, Sarad N, DeCrumpe A, Goswami D, Herrmann S, Morales J, Patel P, Osborne J.
    J Lab Autom; 2015 Oct 01; 20(5):589-600. PubMed ID: 25424384
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.